2026 ICD-10-CM Diagnosis Code Z17.420Hormone receptor negative with human epidermal growth factor receptor 2 positive status
Z17.420 is a billable ICD-10-CM diagnosis code for hormone receptor negative with human epidermal growth factor receptor 2 positive status. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Genetic susceptibility to disease.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for Z17.420.
Present on Admission (POA)Billing
Z17.420 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- HR- with HER2+
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Status (post) - See Also: Presence (of);
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Status(post)
- combined receptor
- negative
- hormone receptor negative with human epidermal growth factor receptor 2 positive
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Advanced Hormone Receptor-Negative Breast Carcinoma|Advanced Hormone Receptor Negative Breast Carcinoma
hormone receptor-negative breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.Hormone Receptor Negative
a finding indicating that the tumor cells in a tissue sample are negative for hormone receptors.Hormone Receptor-Negative Breast Carcinoma|ER and PR Negative Breast Carcinoma|Estrogen Receptor and Progesterone Receptor Negative Breast Carcinoma|Hormone Receptor Negative Breast Adenocarcinoma|Hormone Receptor Negative Breast Carcinoma|Hormone Receptor Negative Breast Carcinoma
breast adenocarcinoma that is negative for hormone receptors.Metastatic Hormone Receptor-Negative Breast Carcinoma|Metastatic Hormone Receptor Negative Breast Carcinoma
hormone receptor-negative breast carcinoma that has spread from its original site of growth to another anatomic site.Recurrent Hormone Receptor-Negative Breast Carcinoma|Recurrent Hormone Receptor Negative Breast Adenocarcinoma|Recurrent Hormone Receptor Negative Breast Carcinoma|Recurrent Hormone Receptor-Negative Breast Adenocarcinoma
the reemergence of hormone receptor-negative breast carcinoma after a period of remission.Refractory Hormone Receptor-Negative Breast Carcinoma|Refractory Hormone Receptor Negative Breast Adenocarcinoma|Refractory Hormone Receptor Negative Breast Carcinoma|Refractory Hormone Receptor-Negative Breast Adenocarcinoma
hormone receptor-negative breast carcinoma that is resistant to treatment.Unresectable Hormone Receptor-Negative Breast Carcinoma|Unresectable Hormone Receptor Negative Breast Carcinoma
hormone receptor-negative breast carcinoma that is not amenable to surgical resection.Advanced Hormone Receptor-Negative Breast Carcinoma|Advanced Hormone Receptor Negative Breast Carcinoma|Advanced Hormone Receptor-Negative Breast Adenocarcinoma
a hormone receptor-negative breast adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.Metastatic Hormone Receptor-Negative Breast Carcinoma|Metastatic Hormone Receptor Negative Breast Carcinoma|Metastatic Hormone Receptor-Negative Breast Adenocarcinoma
hormone receptor-negative breast adenocarcinoma that has spread from its original site of growth to another anatomic site.Recurrent Hormone Receptor-Negative Breast Carcinoma|Recurrent Hormone Receptor Negative Breast Adenocarcinoma|Recurrent Hormone Receptor Negative Breast Carcinoma|Recurrent Hormone Receptor-Negative Breast Adenocarcinoma
the reemergence of hormone receptor-negative breast adenocarcinoma after a period of remission.Refractory Hormone Receptor-Negative Breast Carcinoma|Refractory Hormone Receptor Negative Breast Adenocarcinoma|Refractory Hormone Receptor Negative Breast Carcinoma|Refractory Hormone Receptor-Negative Breast Adenocarcinoma
hormone receptor-negative breast adenocarcinoma that is resistant to treatment.Unresectable Hormone Receptor-Negative Breast Carcinoma|Unresectable Hormone Receptor Negative Breast Carcinoma|Unresectable Hormone Receptor-Negative Breast Adenocarcinoma
hormone receptor-negative breast adenocarcinoma that is not amenable to surgical resection.
Code HistoryHistory
Questions About Z17.420Overview
Is Z17.420 (Hormone receptor negative) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report hormone receptor negative with human epidermal growth factor receptor 2 positive status on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Can Z17.420 be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because hormone receptor negative with human epidermal growth factor receptor 2 positive status describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is Z17.420 exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for hormone receptor negative with human epidermal growth factor receptor 2 positive status on inpatient claims.
